BALAXI PHARMACEUTICALS share news and announcements
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
Formerly Balaxi Ventures
Last close ₹20.91down ₹0.09 (0.43%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹21.00.
52-week range of traded prices to 23 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹115 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 47.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 0.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 40,13985.6% delivered
BALAXI PHARMACEUTICALS disputes and clarifications
17 filed, newest first.
Jul 2026
Jun 2026
24 Jun · Legal
Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
Apr 2026
9 Apr · Legal
The exchange asked on 8 Apr 2026
Mar 2025
10 Mar · Legal
The exchange asked on 10 Mar 2025
Mar 2024
14 Mar · Legal
Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated limited review report not submitted. The response of the Company is awaited.
Mar 2021
10 Mar · Legal
Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED with respect to announcement dated 02-Mar-2021, regarding resignation of Mr. Rakesh Khanna. On basis of above the Company is required to clarify following: 1. No other material reasons other than provided The response of the Company is awaited.
Sep 2020
2 Sep · Legal
Exchange has sought clarification from Balaxi Ventures Limited with respect to announcement dated 27-Aug-2020, regarding a press release dated August 27, 2020, titled "BALAXI VENTURES LIMITED ANNOUNCES ACQUISITION OF 49% STAKE IN GROUP'S ANGOLA BASED DISTRIBUTION ARM. On basis of above the Company is required to clarify following: 1. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";2. Brief details of any governmental or regulatory approvals required for the acquisition;3. Indicative time period for completion of the acquisition;4. Cost of acquisition or the price at which the shares are acquired;5. Nature of consideration - whether cash consideration or share swap and details of the same;6. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.
May 2020
28 May · Legal
The exchange asked on 27 May 2020
Feb 2019
4 Feb · Legal
Exchange has sought clarification from Balaxi Ventures Limited with respect to announcement dated 01-Feb-2019, regarding " Balaxi Ventures Limited has informed the Exchange regarding Board meeting held on February 01, 2019.". On basis of above the Company is required to clarify following: 1. Name of the countries in which the product is launched (in case of international). 2. Whether caters to domestic/ international market; 3. Date of launch; 4. Name of the product; The response of the Company is awaited.
Sep 2017
Aug 2017
Dec 2015
17 Dec · Legal
Clarification by The Anandam Rubber Company Limited Significant price movement has been observed in The Anandam Rubber Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. The Anandam Rubber Company Limitedhas vide its letter inter-alia stated, "There is no material change in the financials, Net worth or Business prospectus of the company. The company is not having any information/announcement (including impending announcement) which in our opinion having a bearing on price/volume behavior in the scrip."